Citius Pharmaceuticals, Inc. (CTXR): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTXR Stock Price Chart Interactive Chart >
CTXR Price/Volume Stats
| Current price | $2.01 | 52-week high | $4.56 |
| Prev. close | $1.98 | 52-week low | $0.87 |
| Day low | $1.97 | Volume | 1,768,900 |
| Day high | $2.05 | Avg. volume | 9,358,634 |
| 50-day MA | $1.96 | Dividend yield | N/A |
| 200-day MA | $1.92 | Market Cap | 293.42M |
Citius Pharmaceuticals, Inc. (CTXR) Company Bio
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Latest CTXR News From Around the Web
Below are the latest news stories about Citius Pharmaceuticals Inc that investors may wish to consider to help them evaluate CTXR as an investment opportunity.
10 New Penny Stocks Redditors are BuyingIn this article, we discuss the 10 new penny stocks Redditors are buying. If you want to skip our detailed analysis of these stocks, go directly to the 5 New Penny Stocks Redditors are Buying. Penny stocks have started gaining traction on popular Reddit forums in the past few months as retail investors, who are […] |
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET. |
Why This Citius Analyst Thinks The Biopharma''s Shares Present 375% Upside PotentialCitius Pharmaceuticals, Inc. (NASDAQ: CTXR ) announced earlier this week an agreement… |
Citius (CTXR) Acquires Dr. Reddy's License for NHL TherapyCitius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications. |
Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. |
CTXR Price Returns
| 1-mo | 5.24% |
| 3-mo | -48.98% |
| 6-mo | 5.79% |
| 1-year | 91.43% |
| 3-year | 13.56% |
| 5-year | -78.73% |
| YTD | 97.06% |
| 2020 | 0.00% |
| 2019 | -1.92% |
| 2018 | -72.63% |
| 2017 | -42.94% |
| 2016 | N/A |
Loading social stream, please wait...